Search in:

Advanced search

Hematology Volume 27, 2022 - Issue 1

Submit an article Journal homepage

Open access

3,139

Views

CrossRef citations to date

Altmetric

Research Article

Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution

Masaki IinoDepartment of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi Prefectural Central Hospital, Kofu, JapanCorrespondence[email protected]

https://orcid.org/0000-0002-3471-0890

Atsushi JingujiDepartment of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi Prefectural Central Hospital, Kofu, Japan

Tomoya SatoDepartment of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi Prefectural Central Hospital, Kofu, Japan

Ayato NakadateDepartment of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi Prefectural Central Hospital, Kofu, Japan

Pages 360-366 | Published online: 20 Mar 2022

Cite this article
https://doi.org/10.1080/16078454.2022.2045725
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–1656.
PubMed Web of Science ®Google Scholar
Contejean A, Resche-Rigon M, Tamburini J, et al. Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2019;104(2):256–262.
PubMed Web of Science ®Google Scholar
Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–19.
PubMed Web of Science ®Google Scholar
Lee JW, Lee S, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019;6(11):e562–e572.
PubMed Web of Science ®Google Scholar
Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550.
PubMed Web of Science ®Google Scholar
Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386(1):11–23.
PubMed Web of Science ®Google Scholar
Zeigler BFC, de Sauvage F, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood. 1994;84(12):4045-4052.
PubMed Web of Science ®Google Scholar
Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.
PubMed Web of Science ®Google Scholar
Nakao S, Hama M, Ohashi H, et al. Reference guide for the treatment of aplastic anemia. 2019 revised version. [cited 2021 September 26]. http://zoketsushogaihan.umin.jp/file/2020/02.pdf.
Google Scholar
Lengline E, Drenou B, Peterlin P, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103(2):212–220.
PubMed Web of Science ®Google Scholar
Ise M, Iizuka H, Kamoda Y, et al. Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study. Int J Hematol. 2020;112(6):787–794.
PubMed Web of Science ®Google Scholar
Yamazaki H, Ohta K, Iida H, et al. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Int J Hematol. 2019;110(2):187–196.
PubMed Web of Science ®Google Scholar
Hwang YY, Gill H, Chan TSY, et al. Eltrombopag in the management of aplastic anemia: real-world experience in a non-trial setting. Hematology. 2018;23(7):399–404.
PubMed Web of Science ®Google Scholar
REVOLADE Tablets prescribing information. (2018). [cited 2021 September 26]. https://www.info.pmda.go.jp/go/pack/3999028F1025_2_05/?view=frame&style=SGML&lang=ja.
Google Scholar
Yamazaki H, Sugimori C, Chuhjo T, et al. Cyclosporine therapy for acquired aplastic anemia: predictive factors for the response and long-term prognosis. Int J Hematol. 2007;85(3):186–190.
PubMed Web of Science ®Google Scholar
Romiplate for S.C. Injection prescribing information. . (2020). [cited 2021 September 26]. https://www.info.pmda.go.jp/go/pack/3999430D1024_1_07/?view=frame&style=XML&lang=ja.
Google Scholar
Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–1825.
PubMed Web of Science ®Google Scholar
Common terminology criteria for adverse events (CTCAE) version 5.0. [cited 2021 September 26]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5(11.pdf.
Google Scholar
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Source J Am Stat Assoc. 1958;53(282):457–481.
Web of Science ®Google Scholar
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
PubMed Web of Science ®Google Scholar
Fan X, Desmond R, Winkler T, et al. Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Adv. 2020;4(8):1700–1710.
PubMed Web of Science ®Google Scholar
Jang JH, Tomiyama Y, Miyazaki K, et al. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. Br J Haematol. 2021;192(1):190–199.
PubMed Web of Science ®Google Scholar
Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann Intern Med. 1999;130(3):193–201.
PubMed Web of Science ®Google Scholar
Rodgers GM, Gilreath JA. Eltrombopag as initial monotherapy for severe aplastic anemia - a case report. Ann Hematol. 2018;97(8):1517–1518.
PubMed Web of Science ®Google Scholar
Cheng H, Wang X, Zhou D, et al. Eltrombopag combined with cyclosporine may have an effective on very severe aplastic anemia. Ann Hematol. 2019;98(8):2009–2011.
PubMed Web of Science ®Google Scholar
Winkler T, Fan X, Cooper J, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019;133(24):2575–2585.
PubMed Web of Science ®Google Scholar
Sun L, Babushok DV. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2020;136(1):36–49.
PubMed Web of Science ®Google Scholar
Ecsedi M, Lengline E, Knol-Bout C, et al. Use of eltrombopag in aplastic anemia in Europe. Ann Hematol. 2019;98(6):1341–1350.
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date